Compositions and methods for diagnosis and treatment of conditions related to aging

A method of treating a condition related to aging, comprising:

• administering one or more fatty acids, or pharmaceutically acceptable salts thereof, to a subject in need thereof,
• wherein the condition related to aging is selected from the group consisting of inflammation, anemia, iron overload, impaired skin integrity, pain, gastrointestinal disorders and problems, Th1-type inflammation, Th2-type inflammation, T-cell dependent B cell proliferation, chronic inflammation, chronic obstructive pulmonary disease (COPD), Crohn's disease, cutaneous responses to tissue damage, fibrosis, hematological oncology, psoriasis, pulmonary fibrosis, pulmonary responses to respiratory infections, restenosis, rheumatoid arthritis, sarcoidosis, stromal biology in tumors, systemic lupus erythematosus (SLE), ulcerative colitis, vascular inflammation, and a disease that is driven or exacerbated by one or more factors selected from the group consisting of alpha smooth muscle actin (αSMA), CD40, CD69, collagen I, collagen III, decorin, e-selectin, eotaxin 3 (CCL26), fibroblast proliferation, human leukocyte antigen-DR isotype (HLA-DR), immunoglobulin G, interferon gamma-induced protein 10 (IP-10/CXCLI0), interferon-inducible T cell alpha chemoattractant (1-TAC/CXCLll), interleukin (IL)-1, IL-la, IL-2, IL-8 (CXCL8), IL-10, IL-17A, IL-17F, keratin 8/81, macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase (MMP)-1, MMP-9, monokine induced by gamma interferon (MIG/CXCL9), plasminogen activation inhibitor I (PAI-I), prostaglandin E2 (PGE2), serum amyloid A, T or B cell proliferation, tissue plasminogen activator (tPA), vascular cell adhesion molecule (VCAM-1), and vascular endothelial growth factor 2 (VEGFR2).